Fangling Cheng

No.1095, Jiefang Avenue
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62-Keap1-Nrf2 pathway.

LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62-Keap1-Nrf2 pathway.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: January 06, 2026

Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling.

Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling.

Journal: Biomarker research

Published: November 14, 2023

A pair of primary colorectal cancer-derived and corresponding synchronous liver metastasis-derived organoid cell lines.

A pair of primary colorectal cancer-derived and corresponding synchronous liver metastasis-derived organoid cell lines.

Journal: Aging

Published: October 27, 2023

Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy.

Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy.

Journal: Cancer letters

Published: June 27, 2023

FAM129A promotes self-renewal and maintains invasive status via stabilizing the Notch intracellular domain in glioma stem cells.

FAM129A promotes self-renewal and maintains invasive status via stabilizing the Notch intracellular domain in glioma stem cells.

Journal: Neuro-oncology

Published: April 21, 2023

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization.

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization.

Journal: Journal for immunotherapy of cancer

Published: August 10, 2022

Establishment and characteristics of GWH04, a new primary human glioblastoma cell line.

Establishment and characteristics of GWH04, a new primary human glioblastoma cell line.

Journal: International journal of oncology

Published: June 06, 2022

TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin αvβ5-Src-Stat3 signaling.

TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin αvβ5-Src-Stat3 signaling.

Journal: Theranostics

Published: November 30, 2021

High expression of TXNDC11 indicated unfavorable prognosis of glioma.

High expression of TXNDC11 indicated unfavorable prognosis of glioma.

Journal: Translational cancer research

Published: July 17, 2021

ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment.

ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment.

Journal: Cancer research

Published: May 08, 2021

Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma.

Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma.

Journal: Frontiers in oncology

Published: August 04, 2020

Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.

Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.

Journal: Cancer gene therapy

Published: November 12, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026